<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8949">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790270</url>
  </required_header>
  <id_info>
    <org_study_id>SB2003-1234</org_study_id>
    <nct_id>NCT00790270</nct_id>
  </id_info>
  <brief_title>Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial</brief_title>
  <official_title>Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether the combination of a muscle relaxant and
      anti-inflammatory drug is more effective at relieving pain in patients with neck strains or
      whiplash than either of the two medications alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Muscle relaxants have been used extensively for neck and back pain since muscle spasm is
      thought to play a role in the cycle of pain and spasm. However, prior studies have
      conflicting results regarding their additive effect when given in addition to analgesics
      such as the NSAIDs. Because they have the potential to lead to adverse events their efficacy
      should be clearly demonstrated before their routine use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Daily for 1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of Rescue Medications</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of patients taking additional rescue medications beyond the study meds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Resumption of Work</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resumption of Work or School</measure>
    <time_frame>next day</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of patients resuming regular activity the day following enrollment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Cervical Strain</condition>
  <arm_group>
    <arm_group_label>Cyclobenzaprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprophen plus Cyclobenzaprine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine</intervention_name>
    <description>5 mg orally every 8 hours as needed</description>
    <arm_group_label>Cyclobenzaprine</arm_group_label>
    <other_name>flexeril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 400 mg every 8 hours as needed</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>motrin, advil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen plus Cyclobenzaprine</intervention_name>
    <description>Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed</description>
    <arm_group_label>Ibuprophen plus Cyclobenzaprine</arm_group_label>
    <other_name>motrin or advil with flexeril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neck pain within 24 hours of injury

        Exclusion Criteria:

          -  Children, allergy or contraindication to any of the study drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>adam singer, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 22, 2012</lastchanged_date>
  <firstreceived_date>November 12, 2008</firstreceived_date>
  <firstreceived_results_date>October 19, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Adam Singer, MD</name_title>
    <organization>Stony Brook University</organization>
  </responsible_party>
  <keyword>Cervical strain</keyword>
  <keyword>whiplash</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>cyclobenzaprine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sprains and Strains</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyclobenzaprine</title>
        </group>
        <group group_id="P2">
          <title>Ibuprofen</title>
        </group>
        <group group_id="P3">
          <title>Ibuprophen Plus Cyclobenzaprine</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclobenzaprine</title>
        </group>
        <group group_id="B2">
          <title>Ibuprofen</title>
        </group>
        <group group_id="B3">
          <title>Ibuprophen Plus Cyclobenzaprine</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="61"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36" spread="13"/>
                <measurement group_id="B2" value="32" spread="10"/>
                <measurement group_id="B3" value="32" spread="10"/>
                <measurement group_id="B4" value="33" spread="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <time_frame>Daily for 1 week</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resumption of Work</title>
        <time_frame>1 week</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Use of Rescue Medications</title>
        <description>the number of patients taking additional rescue medications beyond the study meds</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>number of patients using additionl anlagesics on the day following enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine</title>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
          </group>
          <group group_id="O3">
            <title>Ibuprophen Plus Cyclobenzaprine</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Use of Rescue Medications</title>
            <description>the number of patients taking additional rescue medications beyond the study meds</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resumption of Work or School</title>
        <description>number of patients resuming regular activity the day following enrollment.</description>
        <time_frame>next day</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cyclobenzaprine</title>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
          </group>
          <group group_id="O3">
            <title>Ibuprophen Plus Cyclobenzaprine</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Resumption of Work or School</title>
            <description>number of patients resuming regular activity the day following enrollment.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>next day</time_frame>
      <desc>th number of patients reporting an adverse event on the day following enrollment and each additional day for 1 week.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclobenzaprine</title>
        </group>
        <group group_id="E2">
          <title>Ibuprofen</title>
        </group>
        <group group_id="E3">
          <title>Ibuprophen Plus Cyclobenzaprine</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Singer</name_or_title>
      <organization>Stony Brook U</organization>
      <phone>631 444 7856</phone>
      <email>adam.singer@stonybrook.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
